

**(S)-(+)-2-(p-TOLYLSULFINYL)-2-BUTEN-4-OLIDE: AN ENANTIOMERICALLY PURE MICHAEL ACCEPTOR FOR ASYMMETRIC SYNTHESIS OF 3-SUBSTITUTED 4-BUTANOLIDES. (-)-PODORHIZON.**

Gary H. Posner,\* Timothy P. Kogan, Stephen R. Haines and Leah L. Frye

Department of Chemistry, The Johns Hopkins University, Baltimore, Maryland 21218

**SUMMARY:** A short, reliable, and practical synthesis of (S)-(+)-2-(p-tolylsulfinyl)-2-buten-4-olide has been developed, and the utility of this Michael acceptor for highly enantiocontrolled synthesis of 3-substituted 4-butanolides has been demonstrated.


Because of the importance of many 3-substituted cycloalkanones as biologically active natural products and as widely useful synthetic intermediates, we have developed a program for asymmetric synthesis of these chiral molecules in high enantiomeric purity.<sup>1</sup> Our methodology is based on faithful 1,3-transfer of chirality from the sulfur atom of a temporarily attached, chiral, auxiliary sulfoxide group to the  $\beta$ -vinyl carbon atom of a conjugated enone system during organometallic conjugate addition to enantiomerically pure 2-(arylsulfinyl)-2-cycloalkenones **1** (Ar = p-tolyl or p-anisyl<sup>1f</sup>; R'=H, Me<sup>1e</sup>, or p-tolyl<sup>1e</sup>; n=5 or 6; W=CH<sub>2</sub>; M=Mg, Zn, or Ti). Because of the importance of many 3-substituted and 2,3-disubstituted 4-butanolides ( $\gamma$ -butyrolactones) as biologically active (e.g. anticancer<sup>2</sup>, anti-glaucoma<sup>3</sup>, pheromone<sup>4</sup>, and inducer of streptomycin biosynthesis<sup>5</sup>) natural products and as broadly useful synthons, we have now prepared (S)-(+)-2-(p-tolylsulfinyl)-2-buten-4-olide [(+)-**1a**, W=O, Ar=p-tolyl, R=H, n=5) in virtually complete enantiomeric purity, and we have illustrated its effectiveness as a Michael acceptor for asymmetric synthesis of 3-substituted 4-butanolides by preparation of a vicinally-disubstituted lignan lactone<sup>6</sup> of high enantiomeric purity.

Despite its structural simplicity, relatively small size, and accessibility in racemic form,<sup>7</sup> enantiomerically pure butenolide (+)-**1a** is indeed an exceptionally challenging synthetic target. For example, although we have been able to prepare cyclic bromovinyl orthoester **2a** from 2-bromo-2-buten-4-olide<sup>8</sup> (anhydrous and freshly distilled BF<sub>3</sub>, ethylene oxide, 0°C, 4.5 hr),<sup>9</sup> all attempts at bromine  $\rightarrow$  metal exchange<sup>1,10</sup> using n-butyllithium, t-butyl-lithium, sodium-containing lithium metal, or Rieke magnesium were unsuccessful, as were all attempts at direct lithiation at the 2-position of the corresponding cyclic orthoester **2b**. Following thorough retrosynthetic analysis (bonds a-f in structure **1a**) and unsuccessful experiments to form bonds b-f in butenolide (+)-**1a**, we are now very pleased to report a successful, short, reliable, and practical (i.e. gram scale) synthesis of butenolide (furan-2(5H)-one) (+)-**1a** in virtually complete enantiomeric purity via the accompanying scheme.



pium(III). Complexation with 0.25 equivalents of this europium reagent produced a downfield shift of vinylic H-3 from  $\delta$  8.03 to  $\delta$  11.17 with no detectable splitting of this signal; similar treatment of a racemic 2-arylsulfinyl-2-buten-4-olide produced two new signals of equivalent intensity for H-3 appearing at  $\delta$  11.30 and  $\delta$  11.45. Therefore, butenolide sulfoxide (+)-1a has an extremely high (>98%) enantiomeric purity.

Complexation of butenolide sulfoxide (+)-1a with 1 equivalent of zinc dibromide in 2,5-dimethyltetrahydrofuran (DMTHF)<sup>19</sup> as solvent at  $-78^\circ\text{C}$ , followed first by conjugate addition<sup>16</sup> of 3,4-methylenedioxybenzylmagnesium chloride (3 equivalents) in DMTHF and then by Raney nickel reductive cleavage of the lactone-sulfoxide carbon-sulfur bond, produced 3-benzylated 4-butanolide (—)-6 which was isolated by preparative tlc in 70% overall yield (eq. 1). The negative optical rotation of benzylated lactone (—)-6 [ $[\alpha]_D - 4.7^\circ$  (c 2.3  $\text{CHCl}_3$ ), lit.<sup>2c,17</sup>  $[\alpha]_D - 4.8^\circ$  c, 1.14 ( $\text{CHCl}_3$ )] indicated that this asymmetric carbon-carbon bond formation had occurred on the Si face of the vinylic  $\beta$ -keto sulfoxide system, consistent with our previously proposed chelate model.<sup>1</sup> 2-Acylation of lactone (—)-6 using Koga's procedure<sup>2c</sup> led to trans-2,3-disubstituted lignan lactone (—)-7, (—)-podorhizon, mp.  $128-9^\circ\text{C}$  [lit.<sup>17</sup> mp.  $129-130^\circ\text{C}$ ] [ $[\alpha]_D^{21} = -75.5^\circ$  c 0.2 ( $\text{CHCl}_3$ ) [lit.<sup>17</sup>  $[\alpha]_D^{21} -79.5^\circ$  c 0.6 ( $\text{CHCl}_3$ )] with literature-identical<sup>17</sup> spectroscopic characteristics in 95% enantiomeric purity! (—)-Podorhizon is the antipode of natural (+)-podorhizon, a member of the podophyllotoxin anticancer family.<sup>17</sup> Because d-menthol has recently become commercially available, (R)-(—)-2-(p-tolylsulfinyl)-2-buten-4-olide [(—)-1a] and therefore (+)-podorhizon should be prepared easily using the same reactions as shown in eq. 1.



The ready accessibility of (S)-(+)-2-(p-tolylsulfinyl)-2-buten-4-olide [(+)-1a] and its extraordinary effectiveness as a Michael acceptor<sup>7</sup> for highly (and predictably) enantiocontrolled conjugate addition of organometallic reagents, as exemplified in this preliminary report by preparation of (—)-podorhizon, represent a highly significant and widely useful advance in asymmetric synthesis. We are pursuing study of butenolide sulfoxide 1a and of other unsaturated lactone sulfoxides.

Acknowledgment. We thank the N.I.H. (GM 30052) for financial support and N.A.T.O. for award of an S.E.R.C. Postdoctoral Science Fellowship to T.P.K.

## REFERENCES

1. (a) Posner, G.H., Mallamo, J.P., and Miura, K. J. Amer. Chem. Soc. (1981), **103**, 2886; (b) Posner, G.H., Hulce, M., Mallamo, J.P., Drexler, S., and Clardy, J.J. Org. Chem. (1981), **46**, 5244; (c) Posner, G.H., Mallamo, J.P., Hulce, M. and Frye, L.L. J. Amer. Chem. Soc. (1982), **104**, 4180; (d) Posner, G.H. and Hulce, M. Tetrahedron Lett. (1984), **25**, 379; (e) Posner, G.H., Kogan, T.P. and Hulce, M. Tetrahedron Lett. (1984), **25**, 383; (f) Posner, G.H., Frye, L.L. and Hulce, M. Tetrahedron (1984), **40**, 000; (g) Posner, G.H. and Frye, L.L. Israel J. Chem. (1984), in press.
2. (a) Pettit, G.R. Biosynthetic Products for Cancer Chemotherapy, Plenum Press, N.Y., 1977, Vol. I, p. 97; (b) Jardine, I., in "Anticancer Agents based on Natural Products Models," Cassady, J.M. and Dourour, J.D., Eds., Academic Press, N.Y. 1980, p. 319. (c) Tomioka, K., Mizuguchi, H., and Koga, K. Chem. Pharm. Bull. Japan (1982), **30**, 4304; (d) Shieh, H.-M. and Prestwich, G.D. Tetrahedron Lett. (1982), **23**, 4643.
3. Noordam, A., Maat, L. and Beyerman, H.C. Receuil Trav. Chim. Pays-Bas, (1981), **100**, 441.
4. Vigernon, J.P., Méric, R., Larchevêque, M., Debal, A., Kunesch, G., Zagatti, P., and Gallois, M. Tetrahedron Lett. (1982), **23**, 5051.
5. (a) Mori, K. and Yamane, K. Tetrahedron (1982), **38**, 2919; (b) Mori, K., Tetrahedron (1983), **39**, 3107.
6. For a recent review of lignans, see Ward, R.S. Chem. Soc. Revs. (1982), **11**, 75.
7. (a) Iwai, K., Kosugi, H., and Nda, H. Chem. Lett. (1974), 1237; (b) Watanabe, M., Shirai, K., and Kumamoto T., Chem. Lett. (1975), **855**; (c) Iwai, K., Kosugi, H., and Nda, H. Chem. Lett. (1975), 981; (d) Kosugi, H. and Nda, H. Chem. Lett., (1977), 1491; (e) Kosugi, H. and Uda, H. Bull. Chem. Soc. Japan (1980), **53**, 160.
8. 2-Buten-4-olide was dibrominated ( $\text{Br}_2$ ,  $\text{CCl}_4$ ,  $0^\circ\text{C}$  then  $+25^\circ\text{C}$ , 1.5 hr) and then dehydrobrominated ( $\text{Et}_3\text{N}$ ,  $-78^\circ\text{C}$ , 2 hr  $+25^\circ\text{C}$ , 1.5 hr) in overall 99% yield.
9. Bodenbenner, K., Liebigs Ann. (1959), **623**, 183.
10. Jones, R. G. and Gilman, H. Org. Reactions (1951), **6**, 339.
11. Gschwend, H.W. and Rodriguez, H.R. Org. Reactions (1979), **26**, 1.
12. Jung, M.E. and Light, L.A. Tetrahedron Lett. (1982), **23**, 3851.
13. Neumann, H. and Seebach, D. Tetrahedron Lett. (1976), 4839.
14. M. Hulce, Mallamo, J.P., Frye, L.L., Kogan, T.P. and Posner, G.H. Org. Syntheses, procedure being checked.
15. Posner, G.H., Tang, P.W. and Mallamo, J.P. Tetrahedron Lett. (1978), 3995.
16. For organometallic conjugate additions to 2-arylthio-2-buten-4-olides, see (a) Iwai, K., Kosugi, H., Uda, H., and Kawai, M. Bull. Chem. Soc. Japan, (1977), **55**, 242; (b) Brownbridge, P., Egert, E., Hunt, P.G., Kennard, O., and Warren, S. J. Chem. Soc. Perkin I (1981), 2751; (c) Kido, F., Noda, Y., and Yoshikoshi, A. J. Amer. Chem. Soc. (1982), **104**, 5509; (d) cf. Barbier, P. and Benzra, C. Tetrahedron Lett. (1982), **23**, 3511; (e) cf. Leyendecker, F. and Comte, M.-T. Tetrahedron Lett. (1982), **23**, 5031.
17. Kuhn, M. and von Wartburg, A., Helv. Chim. Acta, (1967), **50**, 1546.

(Received in USA 12 March 1984)